Kanchi Chadha, MD, FACOG, MSCP, supports reconsidering MHT boxed warnings but says the FDA cited no study behind the change.
News|Articles|September 21, 2026
Contemporary OB/GYN Weekly Review: Testosterone evidence, ECV counseling, and more
Author(s)Joshua Fitch, Senior Editor
Fact checked by: Benjamin P. Saylor
Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.
Advertisement
Advertisement
Thank you for visiting the Contemporary OB/GYN website. Take a look at some of our top stories from the past week (Monday, September 14, to Friday, September 18, 2026) and click on each link to read and watch anything you may have missed.
Related to this article
Soma Mandal, MD, MSCP, says removing MHT boxed warnings is overdue but calls for transparency on the FDA's product-specific rationale.
Susan Reed, MD, MPH, MS, and Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, weigh in on FDA boxed warning removals for menopausal hormone therapy.
A recap of the top women's health headlines from October 2026, including FDA approval of pritelivir for refractory HSV, ACOG's new menopause guideline, and more.
The October 30 update from the FDA follows the February 12, 2026 labeling changes to 6 menopausal hormone therapy products in which the agency also removed safety-related boxed warnings.
Stephanie S. Faubion, MD, on choosing between fezolinetant and elinzanetant, liver monitoring, follow-up, and open questions in menopause care.
JoAnn V. Pinkerton, MD, MSCP, reviews 4 pooled elinzanetant analyses from OASIS presented at The Menopause Society Annual Meeting 2026, spanning late perimenopause, sleep, VMS reduction, and safety.
Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.
Advertisement
Advertisement